Published in Healthcare Mergers, Acquisitions and Ventures Week, May 12th, 2007
"These broad indications for use more than double the market potential for Percudyn(TM) outside the U.S. and expand the indications from our original approval for Degenerative Disc Disease in November 2006," stated Interventional Spine, Inc. CEO Walter A. Cuevas. "We believe that our truly percutaneous approach will provide additional benefits to patients and surgeons alike and will become the standard of care for patients suffering with DDD." Mr. Cuevas continued: "In our pilot clinical trial,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.